Changes in prescription volumes and net sales due to climate change
First written in FY2018. 2 of 4 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「The prescription pharmacy business may be affected in its financial results if climate changes increase or decrease opportunities for patients to visit medical institutions, causing prescription volumes to fluctuate.」
The company continues to disclose the risk of fluctuations in medical consultation opportunities and prescription volumes due to climate change. - FY2023-Q2MaterialisedAnnual report
「Although the spread of COVID-19 had temporarily eased during the first quarter, infections rapidly resurged in the second quarter. Combined with the record heat since June this year, this resulted in a slight year-on-year decline in prescription volumes handled at existing stores during the cumulative second-quarter consolidated period.」
The impact of record heat was reflected in a slight year-on-year decline in prescription volumes handled at existing stores, showing that climate-related business volatility risk has materialized in operating results. - FY2019RestatedAnnual report
「The prescription pharmacy business may be affected in its financial results if climate changes increase or decrease opportunities for patients to visit medical institutions, causing prescription volumes to fluctuate.」
The company reiterates the risk of fluctuations in medical consultation opportunities and prescription volumes due to climate change. - FY2018First statedAnnual report
「The prescription pharmacy business may be affected in its financial results if climate changes increase or decrease opportunities for patients to visit medical institutions, causing prescription volumes to fluctuate.」
The company identifies fluctuations in medical consultation opportunities and prescription volumes caused by climate change as a business risk for the prescription pharmacy segment.